Pyrazole derivative
Drugs, in particular, pyrazole derivatives represented by the following general formula (I) which have a calcium release-dependent calcium channel inhibitory effect and medicinal compositions, in particular, calcium release-dependent calcium channel inhibitors containing the above compounds as the active ingredient, (in the formula, each symbol has the following meaning: B: phenylene, a nitrogen-containing, divalent, saturated ring group, or a monocyclic, divalent heteroaromatic ring group which may be substituted with Alk, X: —NR 1 —CR 2 R 3 —, —CR 2 R 3 —NR 1 —, —NR 1 —SO 2 —, —SO 2 —NR 1 — or —CR 4 ═CR 5 —, and A: benzene ring which may have one or more substituents; mono-, di- or tricyclic fused heteroaryl which may have one or more substituents; cycloalkyl which may have one or more substituents; a nitrogen-containing, saturated ring group which may have one or more substituents; lower alkenyl which may have one or more substituents; lower alkynyl which may have one or more substituents; or Alk which may have one or more substituents).
1. A pyrazole compound represented by the following general formula (I) or a pharmaceutically acceptable salt thereof
wherein each symbol has the following meaning,
D: 1H-pyrazol-3-yl which may have 1 to 2 substituents selected from the group consisting of -lower alkyl(“Alk”), -lower alkenyl, -lower alkynyl, halogeno-lower alkyl-, -cycloalkyl, —O-Alk, —COO-Alk and -halogen atom(“Hal”),
n: 0,
B: 1,4-phenylene,
X: —NH—CO—, and
A: aryl which may have one or more substituents of group F; mono- or di-cyclic fused heteroaryl selected from the group consisting of thienyl, furanyl, pyrrolyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, tetrazolyl, triazolyl, thiadiazolyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, indolyl, isoindolyl, isoquinolyl, quinolyl, quinoxanyl, phthalazinyl, imidazo[1,2-a]pyridyl, quinazolinyl and cinnolinyl which may have one or more substituents of group F; cycloalkyl; or Alk, wherein the F group is: -Alk, -lower alkenyl, -lower alkynyl, -Hal, —NH 2 , —NH(Alk), —N(Alk) 2 , —NO 2 , —CN, —OH, —O-Alk, —O—CO-Alk, —SH, —S-Alk, —COO-Alk, —CO-Alk, —CONH 2 , —CONH(Alk), —CON(Alk) 2 , —SO-Alk, —SO 2 -Alk, and —SO 2 NH 2
with the proviso that
when D is 1H-pyrazol-3-yl or 5-methyl-1H-pyrazol-3-yl, A is a group other than methyl.
2. The pyrazole compound or pharmaceutically acceptable salt thereof according to claim 1 , wherein
D is 1H-pyrazol-3-yl which may have 1 to 2 substituents selected from -Alk, halogeno-lower alkyl- and —COO-Alk, and
A is phenyl which may have one or more substituents selected from the group consisting of -Alk, -Hal, —NH 2 , —N(Alk) 2 , —NO 2 , —CN, —OH, —O-Alk and —COO-Alk; mono- or di-cyclic fused heteroaryl selected from the group consisting of thienyl, pyrrolyl, imidazolyl, thiazolyl, oxazolyl, tetrazolyl, triazolyl, thiadiazolyl, pyridyl, pyrazinyl and isoquinolyl, which may be substituted with one or more Alk; cycloalkyl; or Alk.
3. The pyrazole compound or pharmaceutically acceptable salt thereof according to claim 1 , wherein D is 1H-pyrazol-3-yl substituted with at least one trifluoromethyl group.
4. The pyrazole compound or pharmaceutically acceptable salt thereof according to claim 1 , wherein A is monocyclic heteroaryl selected from the group consisting of thiazolyl, thiadiazolyl, thienyl and pyridyl, which may be substituted with one or more Alk.
5. A pharmaceutical composition which comprises a pharmaceutically effective amount of a pyrazole compound represented by the following general formula (I′) or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier
wherein each symbol has the following meaning,
D: 1H-pyrazol-3-yl which may have 1 to 2 substituents selected from the group consisting of -Alk, -lower alkenyl, -lower alkynyl, halogeno-lower alkyl-, -cycloalkyl, —O-Alk, —COO-Alk and -Hal,
n: 0,
B: 1,4-phenylene,
X: —NH—CO—, and
A: aryl which may have one or more substituents of group F; mono- or di-cyclic fused heteroaryl selected from the group consisting of thienyl, furanyl, pyrrolyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, tetrazolyl, triazolyl, thiadiazolyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, indolyl, isoindolyl, isoquinolyl, quinolyl, quinoxanyl, phthalazinyl, imidazo[1,2-a]pyridyl, quinazolinyl and cinnolinyl which may have one or more substituents of group F; cycloalkyl; or Alk, wherein the F group is: -Alk, -lower alkenyl, -lower alkynyl, -Hal, —NH 2 , —NH(Alk), —N(Alk) 2 , —NO 2 , —CN, —OH, —O-Alk, —O—CO-Alk, —SH, —S-Alk, —COO-Alk, —CO-Alk, —CONH 2 , —CONH(Alk), —CON(Alk) 2 , —SO-Alk, —SO 2 -Alk, and —SO 2 NH 2 ,
with the proviso that
when D is 1H-pyrazol-3-yl or 5-methyl-1H-pyrazol-3-yl, A is a group other than methyl.
6. The pharmaceutical composition according to claim 5 , wherein D is 1H-pyrazol-3-yl substituted with at least one trifluoromethyl group.
7. The pharmaceutical composition according to claim 5 , wherein A is monocyclic heteroaryl selected from the group consisting of thiazolyl, thiadiazolyl, thienyl and pyridyl, which may be substituted with Alk.
8. A method for treating bronchial asthma, which comprises administering a pharmaceutical composition comprising a pyrazole compound represented by the following general formula (I′)
wherein each symbol has the following meaning,
D: 1H-pyrazol-3-yl which may have 1 to 2 substituents selected from the group consisting of-Alk, -lower alkenyl, -lower alkynyl, halogeno-lower alkyl-, -cycloalkyl, —O-Alk, —COO-Alk and -Hal,
n: 0,
B: 1,4-phenylene,
X: —NH—CO—, and
A: aryl which may have one or more substituents of group F; mono- or di-cyclic fused heteroaryl selected from the group consisting of thienyl, furanyl, pyrrolyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, tetrazolyl, triazolyl, thiadiazolyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, indolyl, isoindolyl, isoquinolyl, quinolyl, quinoxanyl, phthalazinyl, imidazo[1,2-a]pyridyl, quinazolinyl and cinnolinyl which may have one or more substituents of group F; cycloalkyl; or Alk, wherein the F group is: -Alk, -lower alkenyl, -lower alkynyl, -Hal, —NH 2 , —NH(Alk), —N(Alk) 2 , —NO 2 , —CN, —OH, —O-Alk, —O—CO-Alk, —SH, —S-Alk, —COO-Alk, —CO-Alk, —CONH 2 , —CONH(Alk), —CON(Alk) 2 , —SO-Alk, —SO 2 -Alk, and —SO 2 NH 2 ,
or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, in an effective amount for treating said disease in a patient suffering from or susceptible to said disease.
9. A method for treating rheumatoid arthritis, which comprises administering a pharmaceutical composition comprising a pyrazole compound represented by the following general formula (I′)
wherein each symbol has the following meaning,
D: 1H-pyrazol-3-yl which may have 1 to 2 substituents selected from the group consisting of -Alk, -lower alkenyl, -lower alkynyl, halogeno-lower alkyl-, -cycloalkyl, —O-Alk, —COO-Alk and -Hal,
n: 0,
B: 1,4-phenylene,
X: —NH—CO—, and
A: aryl which may have one or more substituents of group F; mono- or di-cyclic fused heteroaryl selected from the group consisting of thienyl, furanyl, pyrrolyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, tetrazolyl, triazolyl, thiadiazolyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, indolyl, isoindolyl, isoquinolyl, quinolyl, quinoxanyl, phthalazinyl, imidazo[1,2-a]pyridyl, quinazolinyl and cinnolinyl which may have one or more substituents of group F; cycloalkyl; or Alk, wherein the F group is: -Alk, -lower alkenyl, -lower alkynyl, -Hal, —NH 2 , —NH(Alk), —N(Alk) 2 , —NO 2 , —CN, —OH, —O-Alk, —O—CO-Alk, —SH, —S-Alk, —COO-Alk, —CO-Alk, —CONH 2 , —CONH(Alk), —CON(Alk) 2 , —SO-Alk, —SO 2 -Alk, and —SO 2 NH 2 ,
or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, in an effective amount for treating said disease in a patient suffering from or susceptible to said disease.